CL2011001812A1 - Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. - Google Patents
Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.Info
- Publication number
- CL2011001812A1 CL2011001812A1 CL2011001812A CL2011001812A CL2011001812A1 CL 2011001812 A1 CL2011001812 A1 CL 2011001812A1 CL 2011001812 A CL2011001812 A CL 2011001812A CL 2011001812 A CL2011001812 A CL 2011001812A CL 2011001812 A1 CL2011001812 A1 CL 2011001812A1
- Authority
- CL
- Chile
- Prior art keywords
- degeneration
- deferiprone
- cataracts
- glaucoma
- retinopathy
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 4
- 208000002177 Cataract Diseases 0.000 title abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 title abstract 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 229960003266 deferiprone Drugs 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 229910052742 iron Inorganic materials 0.000 title abstract 2
- 206010038848 Retinal detachment Diseases 0.000 title 1
- 208000017442 Retinal disease Diseases 0.000 title 1
- 206010038923 Retinopathy Diseases 0.000 title 1
- 206010064930 age-related macular degeneration Diseases 0.000 title 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- 230000004264 retinal detachment Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14724509P | 2009-01-26 | 2009-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001812A1 true CL2011001812A1 (es) | 2012-02-03 |
Family
ID=42355449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001812A CL2011001812A1 (es) | 2009-01-26 | 2011-07-26 | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023569A1 (enExample) |
| EP (1) | EP2389179A4 (enExample) |
| JP (1) | JP5604631B2 (enExample) |
| KR (1) | KR20120078667A (enExample) |
| CN (1) | CN102348456A (enExample) |
| AP (1) | AP2011005843A0 (enExample) |
| AU (1) | AU2009338093B2 (enExample) |
| BR (1) | BRPI0920492A2 (enExample) |
| CA (1) | CA2750599A1 (enExample) |
| CL (1) | CL2011001812A1 (enExample) |
| CR (1) | CR20110456A (enExample) |
| EA (1) | EA201170970A1 (enExample) |
| IL (1) | IL214291A (enExample) |
| MA (1) | MA33090B1 (enExample) |
| MX (1) | MX2011007947A (enExample) |
| MY (1) | MY161269A (enExample) |
| NI (1) | NI201100148A (enExample) |
| NZ (1) | NZ594728A (enExample) |
| PE (1) | PE20120515A1 (enExample) |
| SG (1) | SG173145A1 (enExample) |
| TN (1) | TN2011000366A1 (enExample) |
| UA (1) | UA103366C2 (enExample) |
| WO (1) | WO2010083582A1 (enExample) |
| ZA (1) | ZA201105514B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016205030B2 (en) * | 2015-01-09 | 2021-04-01 | The Board Of Trustees Of The University Of Illinois | Restoring physiology in iron-deficient organisms using small molecules |
| CN111918646B (zh) | 2017-10-25 | 2022-02-22 | 奇斯药制品公司 | 延迟释放去铁酮片剂及其使用方法 |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| AUPQ262499A0 (en) * | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| WO2004041151A2 (en) * | 2002-11-07 | 2004-05-21 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| EP1601367A2 (en) * | 2003-02-06 | 2005-12-07 | Bioresponse L.L.C. | The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| DK1991225T3 (da) * | 2006-02-22 | 2013-12-16 | Apotex Technologies Inc | Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern |
| JP5290147B2 (ja) | 2006-04-14 | 2013-09-18 | プラナ バイオテクノロジー リミティッド | 加齢黄斑変性症（ａｍｄ）の処置方法 |
| ITMI20061770A1 (it) * | 2006-09-18 | 2008-03-19 | Carlo Ghisalberti | Metodo cosmetico di riduzione delle occhiaie |
| US8501789B2 (en) * | 2007-01-19 | 2013-08-06 | The Trustees Of The University Of Pennsylvania | Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease |
-
2009
- 2009-11-12 JP JP2011546542A patent/JP5604631B2/ja not_active Expired - Fee Related
- 2009-11-12 MY MYPI2011003478A patent/MY161269A/en unknown
- 2009-11-12 SG SG2011053972A patent/SG173145A1/en unknown
- 2009-11-12 UA UAA201110546A patent/UA103366C2/ru unknown
- 2009-11-12 CN CN2009801579837A patent/CN102348456A/zh active Pending
- 2009-11-12 EP EP09838587A patent/EP2389179A4/en not_active Withdrawn
- 2009-11-12 WO PCT/CA2009/001639 patent/WO2010083582A1/en not_active Ceased
- 2009-11-12 BR BRPI0920492A patent/BRPI0920492A2/pt not_active IP Right Cessation
- 2009-11-12 PE PE2011001408A patent/PE20120515A1/es not_active Application Discontinuation
- 2009-11-12 AU AU2009338093A patent/AU2009338093B2/en not_active Ceased
- 2009-11-12 AP AP2011005843A patent/AP2011005843A0/xx unknown
- 2009-11-12 EA EA201170970A patent/EA201170970A1/ru unknown
- 2009-11-12 US US13/138,263 patent/US20130023569A1/en not_active Abandoned
- 2009-11-12 NZ NZ594728A patent/NZ594728A/xx unknown
- 2009-11-12 MX MX2011007947A patent/MX2011007947A/es not_active Application Discontinuation
- 2009-11-12 MA MA34119A patent/MA33090B1/fr unknown
- 2009-11-12 CA CA2750599A patent/CA2750599A1/en not_active Abandoned
- 2009-11-12 KR KR1020117019874A patent/KR20120078667A/ko not_active Withdrawn
-
2011
- 2011-07-26 ZA ZA2011/05514A patent/ZA201105514B/en unknown
- 2011-07-26 TN TN2011000366A patent/TN2011000366A1/fr unknown
- 2011-07-26 CL CL2011001812A patent/CL2011001812A1/es unknown
- 2011-07-26 NI NI201100148A patent/NI201100148A/es unknown
- 2011-07-26 IL IL214291A patent/IL214291A/en not_active IP Right Cessation
- 2011-08-24 CR CR20110456A patent/CR20110456A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170970A1 (ru) | 2012-03-30 |
| MA33090B1 (fr) | 2012-03-01 |
| NI201100148A (es) | 2012-03-06 |
| BRPI0920492A2 (pt) | 2019-07-09 |
| UA103366C2 (ru) | 2013-10-10 |
| AU2009338093A1 (en) | 2011-09-08 |
| JP5604631B2 (ja) | 2014-10-08 |
| EP2389179A1 (en) | 2011-11-30 |
| AU2009338093B2 (en) | 2014-08-28 |
| JP2012515725A (ja) | 2012-07-12 |
| MY161269A (en) | 2017-04-14 |
| TN2011000366A1 (en) | 2013-03-27 |
| EP2389179A4 (en) | 2012-08-29 |
| SG173145A1 (en) | 2011-08-29 |
| MX2011007947A (es) | 2011-12-14 |
| NZ594728A (en) | 2013-03-28 |
| AP2011005843A0 (en) | 2011-08-31 |
| CR20110456A (es) | 2012-05-31 |
| PE20120515A1 (es) | 2012-05-20 |
| WO2010083582A1 (en) | 2010-07-29 |
| IL214291A (en) | 2015-03-31 |
| CA2750599A1 (en) | 2010-07-29 |
| US20130023569A1 (en) | 2013-01-24 |
| IL214291A0 (en) | 2011-09-27 |
| CN102348456A (zh) | 2012-02-08 |
| KR20120078667A (ko) | 2012-07-10 |
| ZA201105514B (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
| NZ705624A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| AR052172A1 (es) | Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares | |
| MX385629B (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
| MX2025004366A (es) | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro | |
| HK1201438A1 (en) | Treatment of ocular disease | |
| CL2014001244A1 (es) | Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras. | |
| WO2009105534A3 (en) | Ophthalmic nsaids as adjuvants | |
| UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
| EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
| MX2014002107A (es) | Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico. | |
| AR054229A1 (es) | Metodos para tratar la angiogenesis ocular edema de retina, isquemia de retina y retinopatia diabetica usando inhibidores selectivos de rtk | |
| WO2015112831A8 (en) | Compositions and methods for treating ocular diseases | |
| WO2011084366A3 (en) | Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions | |
| ATE535243T1 (de) | Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff | |
| MX2009012645A (es) | Formulaciones y metodos para tratar el ojo seco. | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| MY176525A (en) | Therapeutic agent for ocular disease or prophylactic agent for ocular disease | |
| CL2007002386A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| WO2008152507A3 (en) | Compositions and methods for treating ophthalmic disorders | |
| UY33562A (es) | Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma |